PhaseBio Pharmaceuticals, Inc. (PHAS) Stock: Is This Biotechnology Stock Worth Your Investment?


PhaseBio Pharmaceuticals, Inc. (PHAS) is headed up in the market in today’s trading session. The company, one that is focused in the biotechnology industry, is currently trading at $6.75 after heading up 8.17% so far today. As it relates to biotechnology companies, there are several factors that have the ability to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories centered around PHAS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-19-19 11:57AM PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
08:00AM PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019
Mar-18-19 07:29AM PhaseBio’s stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent
Mar-17-19 03:00PM Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiologys 68th Annual Scientific Session
Mar-06-19 08:00AM PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference

However, any time investors are making a decision to invest, investors should look into much more than news, especially in the highly speculative biotechnology space. Here’s what’s happing when it comes to PhaseBio Pharmaceuticals, Inc..

Recent Trends From PHAS

While a move up on a single session, like the gain that we’re seeing from PhaseBio Pharmaceuticals, Inc. may make some investors excited, a single session gain by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is generally important to take a look at trends further out than a single session. As it relates to PHAS, below are the trends that investors have seen:

  • Past 7 Days – In the last seven days, PHAS has generated a change in value that amounts to 81.45%.
  • Past Month – The return on investment from PhaseBio Pharmaceuticals, Inc. over the last month has been 125.15%.
  • Past Three Months – In the last 3 months, the company has generated a return on investment that comes to 95.09%
  • Past 6 Months – Over the previous six months, investors have seen a change that equates to 0 from the company.
  • Year To Date – Since the the last trading session of last year PHAS has produced a return on investment of 118.45%.
  • Annually – Finally, in the past year, investors have seen a change that comes to 0 from PHAS. In this period of time, the stock has sold at a high price of -23.99% and a low price of 164.71%.

Key Ratios

Looking at various ratios associated with a company can give traders a view of just how dangerous and/or rewarding a stock pick might be. Below are a few of the important ratios to look at when looking at PHAS.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the level of short interest. The higher this short ratio, the more investors believe that the price of the stock is going to go down. In general, biotech stocks can come with a higher short ratio. However, we also see a lot of short squeezes in the space. Nonetheless, as it relates to PhaseBio Pharmaceuticals, Inc., it’s short ratio clocks in at 0.07.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure whether or not a company can pay for its debts when they mature based on current assets or quick assets. In the biotechnology industry, many companies are reliant on continued support from investors, the quick and current ratios can be upsetting. However, some better companies in the biotech sector come with positive quick and current ratios. When it comes to PHAS, the quick and current ratios add up to 3.20 and 3.20 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the share price. In this particular case, the book to share value ratio comes in at -151.73.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of the company’s stock. Many early stage biotech companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotechnology sector, this is a very important ratio to think about. As it relates to PHAS, the cash to share value ratio is 1.07.

How Analysts Feel About PhaseBio Pharmaceuticals, Inc.

While it’s not a good idea to blindly follow the opinions of analysts, it is a good idea to use their analysis in order to validate your own due diligence before making an investment decision in the biotechnology space. Here are the recent moves that we’ve seen from analysts as it relates to PHAS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-13-18 Initiated Needham Buy $18
Nov-12-18 Initiated Stifel Buy $14
Nov-12-18 Initiated Citigroup Buy $18

Is Big Money Interested In PhaseBio Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PHAS, here’s what we’re seeing:

Institutions own 64.90% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of PHAS shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

How Many Shares Of PHAS Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 22.65M shares of PhaseBio Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PHAS has a float of 20.49M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PHAS, the short percent of the float is 0.06%.

Financial Results And Expectations

What have ween seen from PHAS in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – At the moment, Wall Street analysts have expectations that PHAS will come up with EPS that totals up to be -1.25, with -0.31 to be reported in the earnings announcement for the current quarter. Although this information is not tide to earnings, because we’re talking on the topic of analysts, PHAS is currently graded as a 1.50 considering a scale that ranges from 1 to 5 on which 1 is the poorest possible analyst grade and 5 is the best possible.
  • 5-Year Sales – Over the past half decade, PhaseBio Pharmaceuticals, Inc. has generated a change in sales volume that comes to a total of 0. Earnings through the past half decade have generated movement in the amount of 0.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is commonly referred to as in the world of humans, the company has generated a change in earnings in the amount of -22.60%. The company has also seen movement in terms of sales that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I’m incredibly dependent on humans. You may not consider this when reading my articles, but it was a human! Although, my creators made it possible for me to learn, it’s quite a bit easier to learn when I receive feedback from human beings. At the bottom of this article, you’ll see a comment section. If you would like for me find other data, tweak the way in which I write something, take a look at information from a different perspective, or you’re interested in telling me anything else, I want to know. To let me in on your thoughts consider leaving a comment below. I will read that lesson and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here